ASTER 70 suggests no clinical benefit from adjuvant chemotherapy in older patients with ER+HER2– breast cancer

Patients with high-risk early-stage ER⁺HER2⁻ breast cancer typically receive both adjuvant chemotherapy and hormonotherapy. However, patients aged ≥70 years have been under-represented in trials testing this approach; therefore, the benefits…